Document is current
Any future updates will be listed below
-
Authors
Zhuang, Kaiting
Wang, Wenjuan
Xu, Cheng
Wang, Siyang
Chen, Yuhao
Zhang, Yingjie
Liang, Yanjun
Zheng, Xumin
Chen, Xiangmei
Feng, Zhe
Cai, Guangyan
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Beijing Municipality (7254312)
National Natural Science Foundation of China (No. 82200762)
National Natural Science Foundation of China (82170686)
China Postdoctoral Science Foundation (2024M754288)
- License Information
-
More Information
Article History
Received: 8 June 2025
Accepted: 29 August 2025
First Online: 29 September 2025
Declarations
:
: hUC-MSCs used in this study were donated by Vcanbio Cell & Gene Engineering Corp. Ltd, which had confirmed that there was initial ethical approval for collection of human cells. The work described has been carried out in accordance with Declaration of Helsinki for experiments involving humans, and that informed consent was obtained for experimentation with human subjects. The animal experiments were conducted in line with the ARRIVE guidelines 2.0. All animal experiments were performed under ethical supervision and approved by the Institutional Animal Care and Use Committee of the Chinese PLA General Hospital in 2022 (Title research: Study on stem cell therapy for acute kidney injury. No. 2022-X18-39. Date of approval: April 18, 2022). This ethical approval also permitted performing experiments using the aforementioned hUC-MSCs.
: Not applicable.
: The authors declare no competing interests.
